Pediatric Blood & Cancer · 2004 · 91 citations · 14 references
MedicineDermatologyOncologyCutaneous OncologyDermatologic SurgeryPediatric DermatologyMesenchymal TumorsPediatric DermatopathologyPediatric SarcomasPediatric Skin TumorsSkin Cancer SurgerySkin TumorsBenign Mesenchymal TumorsDermatofibrosarcoma Protuberans ResectionPediatric Cutaneous SarcomasPediatric Dermatological TherapiesPediatric Magnetic Resonance ImagingPediatric Skin PathologyPediatric Soft Tissue TumorsSoft Tissue Sarcoma Treatment
To document the clinical activity of imatinib mesyalte in a child with a dermatofibrosarcoma protuberans (DFSP). An 18-month-old girl presented with a large extremity DFSP. As surgical resection would have caused unacceptable functional defects, imatinib mesylate was administered to induce tumor reduction and or stabilization. After 23 weeks of therapy, magnetic resonance imaging (MRI) of the tumor showed a reduction in the subcutaneous thickness in the transverse plane. The drug was tolerated well without any adverse reactions. Imatinib mesylate offers a non-surgical alternative for the treatment of large DFSP in children.
14
Elisabeth Buchdunger, Catherine L. Cioffi, Norman M. Law et al. · Journal of Pharmacology and Experimental Therapeutics · 2000 · 1.3K citations
Medicine, Oncology, Pharmacology +15
Dermatofibrosarcoma protuberans.A study of 115 cases
Herbert B. Taylor, Elson B. Helwig · Cancer · 1962 · 532 citations
Medicine, Dermatology, Oncology +8
Marie‐Pierre Simon, Florence Pédeutour, Nicolas Sirvent et al. · Nature Genetics · 1997 · 528 citations
Life Sciences, Dermatology, Genetics +14
Dermatofibrosarcoma protuberans: treatment and prognosis.
Emiel J. Rutgers, Kroon Bb, Albus-Lutter Ce et al. · PubMed · 1992 · 288 citations
Medicine, Dermatology, Oncology +10